ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. December 11, 2019
ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. November 21, 2019
ProQR to Present at the JMP Securities Life Sciences Conference Press release LEIDEN, the Netherlands and CAMBRIDGE, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. June 03, 2019
ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day Press release LEIDEN, the Netherlands & CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. January 29, 2019